|
|
Elan Corporation, plc
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Russel Katz, Head of FDA Neurology is very clear that they wont approve an AD drug solely on the basis of a secondary endpoint such as PIB Pet and change in CSF Tau. Want real effect on cognitive and functional. EOMhttp://www.alzforum.org/res/com/videogallery/default.asp Watch these two videos. Katz is willing to give priority review and also accept a drug that has risk if efficacy is strong. 3. The Progress of Drug Development. A group discussion at the 2008 ICAD conference in Chicago, moderated by Maria Carillo of the Alzheimer's Association. Features Paul Aisen, UCSC/ADCS; Richard Frank, GE Healthcare, Russell Katz, FDA; Marcelle Morrison-Bogorad, NIA; Lennart Mucke, UCSF/Gladstone Institute, Dale Schenk, Elan Pharmaceuticals; Eric Siemers, Eli Lilly and Company 4. Approving Drugs for Alzheimer's. A conversation with Russell Katz, FDA |
||||||||||||
|
|
return to message board, top of board |
